Clinical Trial Update: Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial of bevacizumab (rhuMAb VEGF) for metastatic renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Renal Cell Cancer | Phase 3 | Status: WITHDRAWN